Thrombocytopenia

Phase II SBIR grant to develop long-acting cytokine conjugates

Published in Cancer Weekly, January 14th, 2003

Bolder BioTechnology, Inc., announced that it has been awarded a $798,000 phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute of The National Institutes of Health (NIH).

The grant, entitled "Cytokine Conjugates for Treating Thrombocytopenia", supports research to develop long acting, second generation forms of interleukin-11 (IL-11) for the treatment of chemotherapy-induced thrombocytopenia. Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

George (Joe) Cox, PhD, company president and principal investigator for the grant, stated, "This continuing grant award...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry